Increased miR-155-5p and reduced miR-148a-3p contribute to the suppression of osteosarcoma cell death
Osteosarcoma (OS) is the most common cancer of bone and the 5th leading cause of cancer-related death in young adults. Currently, 5-year survival rates have plateaued at ~70% for patients with localized disease. Those with disseminated disease have an ~20% 5-year survival. An improved understanding...
Saved in:
Published in | Oncogene Vol. 35; no. 40; pp. 5282 - 5294 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
London
Nature Publishing Group UK
06.10.2016
Nature Publishing Group |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Osteosarcoma (OS) is the most common cancer of bone and the 5th leading cause of cancer-related death in young adults. Currently, 5-year survival rates have plateaued at ~70% for patients with localized disease. Those with disseminated disease have an ~20% 5-year survival. An improved understanding of the molecular genetics of OS may yield new approaches to improve outcomes for OS patients. To this end, we applied murine models that replicate human OS to identify and understand dysregulated microRNAs (miRNAs) in OS. miRNA expression patterns were profiled in murine primary osteoblasts, osteoblast cultures and primary OS cell cultures (from primary and paired metastatic locations) isolated from two genetically engineered murine models of OS. The differentially expressed miRNA were further assessed by a cross-species comparison with human osteoblasts and OS cultures. We identified miR-155-5p and miR-148a-3p as deregulated in OS. miR-155-5p suppression or miR-148a-3p overexpression potently reduced proliferation and induced apoptosis in OS cells, yet strikingly, did not impact normal osteoblasts. To define how these miRNAs regulated OS cell fate, we used an integrated computational approach to identify putative candidate targets and then correlated these with the cell biological impact. Although we could not resolve the mechanism through which miR-148a-3p impacts OS, we identified that miR-155-5p overexpression suppressed its target
Ripk1
(receptor (TNFRSF)-interacting serine–threonine kinase 1) expression, and miR-155-5p inhibition elevated
Ripk1
levels.
Ripk1
is directly involved in apoptosis/necroptosis. In OS cells, small interfering RNA against
Ripk1
prevented cell death induced by the sequestration of miR-155-5p. Collectively, we show that miR-148a-3p and miR-155-5p are species-conserved deregulated miRNA in OS. Modulation of these miRNAs was specifically toxic to tumor cells but not normal osteoblasts, raising the possibility that these may be tractable targets for miRNA-based therapies for OS. |
---|---|
AbstractList | Osteosarcoma (OS) is the most common cancer of bone and the 5th leading cause of cancer-related death in young adults. Currently, 5-year survival rates have plateaued at ~70% for patients with localized disease. Those with disseminated disease have an ~20% 5-year survival. An improved understanding of the molecular genetics of OS may yield new approaches to improve outcomes for OS patients. To this end, we applied murine models that replicate human OS to identify and understand dysregulated microRNAs (miRNAs) in OS. miRNA expression patterns were profiled in murine primary osteoblasts, osteoblast cultures and primary OS cell cultures (from primary and paired metastatic locations) isolated from two genetically engineered murine models of OS. The differentially expressed miRNA were further assessed by a cross-species comparison with human osteoblasts and OS cultures. We identified miR-155-5p and miR-148a-3p as deregulated in OS. miR-155-5p suppression or miR-148a-3p overexpression potently reduced proliferation and induced apoptosis in OS cells, yet strikingly, did not impact normal osteoblasts. To define how these miRNAs regulated OS cell fate, we used an integrated computational approach to identify putative candidate targets and then correlated these with the cell biological impact. Although we could not resolve the mechanism through which miR-148a-3p impacts OS, we identified that miR-155-5p overexpression suppressed its target Ripk1 (receptor (TNFRSF)-interacting serine-threonine kinase 1) expression, and miR-155-5p inhibition elevated Ripk1 levels. Ripk1 is directly involved in apoptosis/necroptosis. In OS cells, small interfering RNA against Ripk1 prevented cell death induced by the sequestration of miR-155-5p. Collectively, we show that miR-148a-3p and miR-155-5p are species-conserved deregulated miRNA in OS. Modulation of these miRNAs was specifically toxic to tumor cells but not normal osteoblasts, raising the possibility that these may be tractable targets for miRNA-based therapies for OS. Oncogene (2016) 35, 5282-5294; doi: 10.1038/onc.2016.68; published online 4 April 2016 Osteosarcoma (OS) is the most common cancer of bone and the 5th leading cause of cancer-related death in young adults. Currently, 5-year survival rates have plateaued at ~70% for patients with localized disease. Those with disseminated disease have an ~20% 5-year survival. An improved understanding of the molecular genetics of OS may yield new approaches to improve outcomes for OS patients. To this end, we applied murine models that replicate human OS to identify and understand dysregulated microRNAs (miRNAs) in OS. miRNA expression patterns were profiled in murine primary osteoblasts, osteoblast cultures and primary OS cell cultures (from primary and paired metastatic locations) isolated from two genetically engineered murine models of OS. The differentially expressed miRNA were further assessed by a cross-species comparison with human osteoblasts and OS cultures. We identified miR-155-5p and miR-148a-3p as deregulated in OS. miR-155-5p suppression or miR-148a-3p overexpression potently reduced proliferation and induced apoptosis in OS cells, yet strikingly, did not impact normal osteoblasts. To define how these miRNAs regulated OS cell fate, we used an integrated computational approach to identify putative candidate targets and then correlated these with the cell biological impact. Although we could not resolve the mechanism through which miR-148a-3p impacts OS, we identified that miR-155-5p overexpression suppressed its target Ripk1 (receptor (TNFRSF)-interacting serine-threonine kinase 1) expression, and miR-155-5p inhibition elevated Ripk1 levels. Ripk1 is directly involved in apoptosis/necroptosis. In OS cells, small interfering RNA against Ripk1 prevented cell death induced by the sequestration of miR-155-5p. Collectively, we show that miR-148a-3p and miR-155-5p are species-conserved deregulated miRNA in OS. Modulation of these miRNAs was specifically toxic to tumor cells but not normal osteoblasts, raising the possibility that these may be tractable targets for miRNA-based therapies for OS. Osteosarcoma (OS) is the most common cancer of bone and the 5th leading cause of cancer-related death in young adults. Currently, 5-year survival rates have plateaued at ~ 70% for patients with localized disease. Those with disseminated disease have an ~ 20% 5-year survival. An improved understanding of the molecular genetics of OS may yield new approaches to improve outcomes for OS patients. To this end, we applied murine models that replicate human OS to identify and understand dysregulated microRNAs (miRNAs) in OS. miRNA expression patterns were proled in murine primary osteoblasts, osteoblast cultures and primary OS cell cultures (from primary and paired metastatic locations) isolated from two genetically engineered murine models of OS. The differentially expressed miRNA were further assessed by a cross-species comparison with human osteoblasts and OS cultures. We identied miR-155-5p and miR-148a-3p as deregulated in OS. miR-155-5p suppression or miR-148a-3p overexpression potently reduced proliferation and induced apoptosis in OS cells, yet strikingly, did not impact normal osteoblasts. To dene how these miRNAs regulated OS cell fate, we used an integrated computational approach to identify putative candidate targets and then correlated these with the cell biological impact. Although we could not resolve the mechanism through which miR-148a-3p impacts OS, we identied that miR-155-5p overexpression suppressed its target Ripk1 (receptor (TNFRSF)-interacting serinethreonine kinase 1) expression, and miR-155-5p inhibition elevated Ripk1 levels. Ripk1 is directly involved in apoptosis/necroptosis. In OS cells, small interfering RNA against Ripk1 prevented cell death induced by the sequestration of miR-155-5p. Collectively, we show that miR-148a-3p and miR-155-5p are species-conserved deregulated miRNA in OS. Modulation of these miRNAs was specically toxic to tumor cells but not normal osteoblasts, raising the possibility that these may be tractable targets for miRNA-based therapies for OS. Osteosarcoma (OS) is the most common cancer of bone and the 5th leading cause of cancer-related death in young adults. Currently, 5-year survival rates have plateaued at ~70% for patients with localized disease. Those with disseminated disease have an ~20% 5-year survival. An improved understanding of the molecular genetics of OS may yield new approaches to improve outcomes for OS patients. To this end, we applied murine models that replicate human OS to identify and understand dysregulated microRNAs (miRNAs) in OS. miRNA expression patterns were profiled in murine primary osteoblasts, osteoblast cultures and primary OS cell cultures (from primary and paired metastatic locations) isolated from two genetically engineered murine models of OS. The differentially expressed miRNA were further assessed by a cross-species comparison with human osteoblasts and OS cultures. We identified miR-155-5p and miR-148a-3p as deregulated in OS. miR-155-5p suppression or miR-148a-3p overexpression potently reduced proliferation and induced apoptosis in OS cells, yet strikingly, did not impact normal osteoblasts. To define how these miRNAs regulated OS cell fate, we used an integrated computational approach to identify putative candidate targets and then correlated these with the cell biological impact. Although we could not resolve the mechanism through which miR-148a-3p impacts OS, we identified that miR-155-5p overexpression suppressed its target Ripk1 (receptor (TNFRSF)-interacting serine–threonine kinase 1) expression, and miR-155-5p inhibition elevated Ripk1 levels. Ripk1 is directly involved in apoptosis/necroptosis. In OS cells, small interfering RNA against Ripk1 prevented cell death induced by the sequestration of miR-155-5p. Collectively, we show that miR-148a-3p and miR-155-5p are species-conserved deregulated miRNA in OS. Modulation of these miRNAs was specifically toxic to tumor cells but not normal osteoblasts, raising the possibility that these may be tractable targets for miRNA-based therapies for OS. |
Audience | Academic |
Author | Martin, T J Chalk, A M Zannettino, A C Baker, E K Ng, A J M Purton, L E Lu, J Bhattacharya, S Walkley, C R |
Author_xml | – sequence: 1 givenname: S surname: Bhattacharya fullname: Bhattacharya, S organization: St Vincent’s Institute of Medical Research and Department of Medicine, St Vincent’s Hospital, University of Melbourne – sequence: 2 givenname: A M surname: Chalk fullname: Chalk, A M organization: St Vincent’s Institute of Medical Research and Department of Medicine, St Vincent’s Hospital, University of Melbourne – sequence: 3 givenname: A J M surname: Ng fullname: Ng, A J M organization: St Vincent’s Institute of Medical Research and Department of Medicine, St Vincent’s Hospital, University of Melbourne – sequence: 4 givenname: T J surname: Martin fullname: Martin, T J organization: St Vincent’s Institute of Medical Research and Department of Medicine, St Vincent’s Hospital, University of Melbourne – sequence: 5 givenname: A C surname: Zannettino fullname: Zannettino, A C organization: Myeloma Research Laboratory, School of Medicine, Faculty of Health Sciences, University of Adelaide, Cancer Theme, South Australian Health and Medical Research Institute – sequence: 6 givenname: L E surname: Purton fullname: Purton, L E organization: St Vincent’s Institute of Medical Research and Department of Medicine, St Vincent’s Hospital, University of Melbourne, ACRF Rational Drug Discovery Centre, St Vincent’s Institute of Medical Research – sequence: 7 givenname: J surname: Lu fullname: Lu, J organization: Department of Genetics and Yale Stem Cell Center, Yale University – sequence: 8 givenname: E K surname: Baker fullname: Baker, E K organization: St Vincent’s Institute of Medical Research and Department of Medicine, St Vincent’s Hospital, University of Melbourne – sequence: 9 givenname: C R surname: Walkley fullname: Walkley, C R email: cwalkley@svi.edu.au organization: St Vincent’s Institute of Medical Research and Department of Medicine, St Vincent’s Hospital, University of Melbourne, ACRF Rational Drug Discovery Centre, St Vincent’s Institute of Medical Research |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/27041566$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kc1rHSEUxaWkNC9pV90XoZtCO6_q-LkMIW0DgULJXnx6TSa80anOLPLf1-El6QehuFCuv3s83nOCjlJOgNBbSraU9PpzTn7LCJVbqV-gDeVKdkIYfoQ2xAjSGdazY3RS6x0hRBnCXqFjpginQsoNgsvkC7gKAY_Dj44K0YkJuxRwgbD4xzLXrusn7HOay7BbZsBzxvMt4LpMU4Fah5xwjjjXGXJ1xefRYQ_7PQ7g5tvX6GV0-wpvHvZTdP3l4vr8W3f1_evl-dlV54UWcxej4wJc1CIGSqM2AXpipITgPQ0muJ6LnYwBeC95s0QV79ku-ECNWs-n6MNBdir55wJ1tuNQVxcuQV6qpbpXTVAx0tD3_6B3eSmpmbNMttkYqon8H0U1k6xXirPf1I3bgx1SzHNxfn3annHZxkyoWKntM1RbAcahDRbi0Op_NXw8NPiSay0Q7VSG0ZV7S4ldk7ctebsmb6Vu9LsHq8tuhPDEPkbdgE8HoLardAPlj788o_cLaZW1ww |
CODEN | ONCNES |
CitedBy_id | crossref_primary_10_1080_14728222_2023_2263908 crossref_primary_10_2147_CMAR_S302777 crossref_primary_10_1016_j_jconrel_2019_02_007 crossref_primary_10_1111_odi_14655 crossref_primary_10_3892_ijmm_2018_3458 crossref_primary_10_1007_s10555_017_9724_7 crossref_primary_10_1002_jcb_26601 crossref_primary_10_1177_1010428317711539 crossref_primary_10_1038_s41420_022_01261_5 crossref_primary_10_1097_CORR_0000000000000867 crossref_primary_10_1007_s11626_022_00718_2 crossref_primary_10_1042_BST20160131 crossref_primary_10_3390_cancers12082185 crossref_primary_10_1186_s13046_017_0602_5 crossref_primary_10_1016_j_biopha_2020_109880 crossref_primary_10_1038_s41419_018_0813_5 crossref_primary_10_1111_1759_7714_14834 crossref_primary_10_1155_2022_3391878 crossref_primary_10_1016_j_jbo_2018_02_004 crossref_primary_10_1016_j_ejphar_2019_03_034 crossref_primary_10_1007_s10637_018_0624_7 crossref_primary_10_3389_fonc_2021_731598 crossref_primary_10_1016_j_gene_2018_01_049 crossref_primary_10_1016_j_tjog_2022_09_009 crossref_primary_10_1007_s12094_019_02104_z crossref_primary_10_1038_s41420_021_00596_9 crossref_primary_10_1111_jcmm_14045 crossref_primary_10_1042_BSR20160542 crossref_primary_10_1016_j_fct_2020_111258 crossref_primary_10_1016_j_taap_2019_114616 crossref_primary_10_1111_cas_13177 crossref_primary_10_1177_10732748221076683 crossref_primary_10_1186_s40246_024_00602_y crossref_primary_10_1007_s10495_022_01760_x crossref_primary_10_1016_j_ejpb_2018_04_018 crossref_primary_10_3390_cancers14061546 crossref_primary_10_18632_aging_202706 crossref_primary_10_3727_096504017X14850134190255 crossref_primary_10_1096_fj_201801711R crossref_primary_10_3390_ijms24119392 crossref_primary_10_1016_j_envint_2021_106782 crossref_primary_10_1080_17501911_2024_2354653 crossref_primary_10_3892_ol_2018_8932 crossref_primary_10_1186_s10020_022_00591_5 crossref_primary_10_3892_etm_2018_6845 crossref_primary_10_3892_mmr_2023_13058 crossref_primary_10_1002_kjm2_12442 crossref_primary_10_1016_j_intimp_2023_110603 crossref_primary_10_1016_j_gene_2017_09_027 crossref_primary_10_1016_j_biopha_2019_109627 |
Cites_doi | 10.1038/82732 10.1038/nature13905 10.1158/1078-0432.CCR-11-1714 10.3892/ol.2012.866 10.1002/ijc.2910420408 10.1038/nrm3683 10.1186/gm406 10.1007/s11010-013-1786-4 10.1016/j.molcel.2015.07.032 10.1073/pnas.0804438105 10.1038/onc.2012.305 10.1111/j.1349-7006.2010.01697.x 10.3892/etm.2014.1942 10.1073/pnas.1201516109 10.1373/clinchem.2010.144709 10.1002/ijc.25715 10.1016/j.jbi.2011.05.002 10.1038/cdd.2012.90 10.1002/cncr.24121 10.1371/journal.pone.0127386 10.3892/ijo.2012.1724 10.1136/mp.55.6.389 10.4049/jimmunol.179.8.5082 10.1016/S0092-8674(04)00045-5 10.1006/dbio.1999.9523 10.1128/MCB.17.3.1490 10.7150/ijms.5528 10.1016/j.devcel.2008.03.012 10.1038/sj.cdd.4402085 10.1007/s11010-013-1682-y 10.1200/JCO.2002.20.3.776 10.1073/pnas.0909311106 10.1007/s11010-013-1677-8 10.1016/j.bone.2013.02.016 10.1089/dna.2006.0505 10.1186/1750-1172-8-7 10.1080/07357900802491477 10.1002/pbc.21078 10.1101/gad.1974211 10.1007/s12032-011-0134-3 10.1016/j.cell.2008.03.036 10.1016/S8756-3282(02)00858-X 10.1158/1078-0432.CCR-07-5090 10.1056/NEJMoa1209026 10.1073/pnas.93.20.10923 10.1073/pnas.0707900105 10.1002/jcb.10614 10.1016/0092-8674(95)90072-1 10.1038/bjc.2013.549 10.1158/0008-5472.CAN-11-2663 10.1007/s13277-014-2565-x 10.1101/gad.1656808 10.1371/journal.pone.0053906 |
ContentType | Journal Article |
Copyright | Macmillan Publishers Limited 2016 COPYRIGHT 2016 Nature Publishing Group Copyright Nature Publishing Group Oct 6, 2016 Macmillan Publishers Limited 2016. |
Copyright_xml | – notice: Macmillan Publishers Limited 2016 – notice: COPYRIGHT 2016 Nature Publishing Group – notice: Copyright Nature Publishing Group Oct 6, 2016 – notice: Macmillan Publishers Limited 2016. |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 3V. 7TM 7TO 7U9 7X7 7XB 88A 88E 8AO 8C1 8FD 8FE 8FH 8FI 8FJ 8FK 8G5 ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FR3 FYUFA GHDGH GNUQQ GUQSH H94 HCIFZ K9. LK8 M0S M1P M2O M7P MBDVC P64 PQEST PQQKQ PQUKI PRINS Q9U RC3 |
DOI | 10.1038/onc.2016.68 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef ProQuest Central (Corporate) Nucleic Acids Abstracts Oncogenes and Growth Factors Abstracts Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Biology Database (Alumni Edition) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database Technology Research Database ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Research Library (Alumni Edition) ProQuest Central (Alumni) ProQuest Central ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central Korea Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student Research Library Prep AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) Research Library Biological Science Database Research Library (Corporate) Biotechnology and BioEngineering Abstracts ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic Genetics Abstracts |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Research Library Prep ProQuest Central Student Oncogenes and Growth Factors Abstracts Technology Research Database ProQuest Central Essentials Nucleic Acids Abstracts ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College Research Library (Alumni Edition) ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central China ProQuest Biology Journals (Alumni Edition) ProQuest Central Genetics Abstracts Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Biological Science Collection AIDS and Cancer Research Abstracts ProQuest Research Library ProQuest Medical Library (Alumni) ProQuest Public Health Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest Central Basic ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Engineering Research Database ProQuest One Academic ProQuest Central (Alumni) |
DatabaseTitleList | AIDS and Cancer Research Abstracts Research Library Prep Research Library Prep MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Chemistry Biology |
EISSN | 1476-5594 |
EndPage | 5294 |
ExternalDocumentID | 4205851551 A465660152 10_1038_onc_2016_68 27041566 |
Genre | Research Support, Non-U.S. Gov't Journal Article Feature |
GroupedDBID | --- -Q- 0R~ 123 29N 2WC 36B 39C 3V. 4.4 406 53G 5RE 70F 7X7 88A 88E 8AO 8C1 8FE 8FH 8FI 8FJ 8G5 8R4 8R5 AACDK AANZL AASML AATNV AAWBL AAZLF ABAKF ABJNI ABLJU ABUWG ABZZP ACAOD ACGFO ACGFS ACKTT ACMJI ACPRK ACRQY ACZOJ ADBBV ADFRT ADHDB AEJRE AEMSY AENEX AEVLU AEXYK AFBBN AFKRA AFSHS AGEZK AGHAI AGQEE AHMBA AHSBF AIGIU AILAN AJRNO ALFFA ALIPV ALMA_UNASSIGNED_HOLDINGS AMYLF ASPBG AVWKF AXYYD AZFZN AZQEC BBNVY BENPR BHPHI BKKNO BPHCQ BVXVI CCPQU CS3 DIK DNIVK DPUIP DU5 DWQXO E3Z EAP EBLON EBS EE. EIOEI EJD ESX F5P FDQFY FEDTE FERAY FIGPU FIZPM FSGXE FYUFA GNUQQ GUQSH HCIFZ HMCUK HVGLF HZ~ IAO IHR INH INR ITC IWAJR JSO JZLTJ KQ8 L7B LK8 M0L M1P M2O M7P N9A NAO NQJWS NXXTH O9- OK1 OVD P2P PQQKQ PROAC PSQYO Q2X RNT RNTTT SNX SNYQT SOHCF SRMVM SWTZT TAOOD TBHMF TDRGL TEORI TSG UKHRP W2D WH7 AAYZH CGR CUY CVF ECM EIF NPM AAYXX CITATION 7TM 7TO 7U9 7XB 8FD 8FK FR3 H94 K9. MBDVC P64 PQEST PQUKI PRINS Q9U RC3 |
ID | FETCH-LOGICAL-c585t-ffa45eaf85fd11f89de30966edcc1d9da345b6fde436448a17432bdcd1971743 |
IEDL.DBID | 8C1 |
ISSN | 0950-9232 |
IngestDate | Thu Oct 24 23:27:49 EDT 2024 Tue Nov 19 05:28:17 EST 2024 Tue Nov 19 04:32:47 EST 2024 Tue Nov 19 21:26:34 EST 2024 Tue Nov 12 22:43:49 EST 2024 Thu Nov 21 22:21:36 EST 2024 Wed Oct 16 00:59:23 EDT 2024 Fri Oct 11 20:46:58 EDT 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 40 |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c585t-ffa45eaf85fd11f89de30966edcc1d9da345b6fde436448a17432bdcd1971743 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://www.nature.com/articles/onc201668.pdf |
PMID | 27041566 |
PQID | 1826237742 |
PQPubID | 36330 |
PageCount | 13 |
ParticipantIDs | proquest_miscellaneous_1837309720 proquest_journals_2641591806 proquest_journals_1826237742 gale_infotracmisc_A465660152 gale_infotracacademiconefile_A465660152 crossref_primary_10_1038_onc_2016_68 pubmed_primary_27041566 springer_journals_10_1038_onc_2016_68 |
PublicationCentury | 2000 |
PublicationDate | 2016-10-06 |
PublicationDateYYYYMMDD | 2016-10-06 |
PublicationDate_xml | – month: 10 year: 2016 text: 2016-10-06 day: 06 |
PublicationDecade | 2010 |
PublicationPlace | London |
PublicationPlace_xml | – name: London – name: England – name: New York |
PublicationTitle | Oncogene |
PublicationTitleAbbrev | Oncogene |
PublicationTitleAlternate | Oncogene |
PublicationYear | 2016 |
Publisher | Nature Publishing Group UK Nature Publishing Group |
Publisher_xml | – name: Nature Publishing Group UK – name: Nature Publishing Group |
References | Gougelet, Pissaloux, Besse, Perez, Duc, Dutour (CR14) 2011; 129 Mutsaers, Ng, Baker, Russell, Chalk, Wall (CR20) 2013; 55 Kelly, Haibe-Kains, Janeway, Hill, Howe, Goldsmith (CR32) 2013; 5 Neale, Su, Morton, Phelps, Gorlick, Lock (CR31) 2008; 14 Batanian, Cavalli, Aldosari, Ma, Sotelo-Avila, Ramos (CR40) 2002; 55 Festjens, Vanden Berghe, Cornelis, Vandenabeele (CR43) 2007; 14 Hanoun, Delpu, Suriawinata, Bournet, Bureau, Selves (CR23) 2010; 56 Parkin, Stiller, Draper, Bieber (CR1) 1988; 42 Li, Song, Wang, Luo, Yu (CR33) 2013; 380 Zheng, Liang, Wang, Huang, Cao, Zha (CR34) 2011; 17 Walkley, Qudsi, Sankaran, Perry, Gostissa, Roth (CR19) 2008; 22 Png, Yoshida, Zhang, Shu, Lee, Rimner (CR27) 2011; 25 Grimm, Stanger, Leder (CR42) 1996; 93 Mirabello, Troisi, Savage (CR4) 2009; 115 Lu, Guo, Ebert, Zhang, Peng, Bosco (CR57) 2008; 14 Cheng, Bahal, Babar, Pincus, Barrera, Liu (CR52) 2015; 518 Atkins, Bouralexis, Evdokiou, Hay, Labrinidis, Zannettino (CR55) 2002; 31 Stanger, Leder, Lee, Kim, Seed (CR44) 1995; 81 Hu, Zhang, Cai, Huang, Cai (CR13) 2012; 4 Wang, Du, Wang (CR45) 2008; 133 Janssen, Reesink, Lawitz, Zeuzem, Rodriguez-Torres, Patel (CR54) 2013; 368 Lv, Guo, Li, Jiang (CR37) 2014; 8 Kobayashi, Lu, Cobb, Rodda, McMahon, Schipani (CR7) 2008; 105 Jouan-Lanhouet, Arshad, Piquet-Pellorce, Martin-Chouly, Le Moigne-Muller, Van Herreweghe (CR48) 2012; 19 Babar, Cheng, Booth, Liang, Weidhaas, Saltzman (CR53) 2012; 109 Allan, Ho, Umezawa, Hata, Makishima, Gillespie (CR21) 2003; 90 Bartel (CR5) 2004; 116 Olsen, Ambros (CR6) 1999; 216 Tili, Michaille, Cimino, Costinean, Dumitru, Adair (CR30) 2007; 179 Houghton, Morton, Tucker, Payne, Favours, Cole (CR56) 2007; 49 Neilsen, Noll, Mattiske, Bracken, Gregory, Schulz (CR29) 2013; 32 Dweep, Sticht, Pandey, Gretz (CR28) 2011; 44 Zhang, Harashima, Moritani, Huang, Harada (CR49) 2015; 10 Inose, Ochi, Kimura, Fujita, Xu, Sato (CR9) 2009; 106 Bielack, Kempf-Bielack, Delling, Exner, Flege, Helmke (CR3) 2002; 20 Wu, Zhong, Gao, Zhai, Ding, Wu (CR11) 2013; 10 Tang, Lin, Cai, Tang, Zhou (CR15) 2013; 6 Yen, Chen, Chen, Chen, Chen, Chiou (CR39) 2009; 35 Dondelinger, Jouan-Lanhouet, Divert, Theatre, Bertin, Gough (CR50) 2015; 60 Ma, Zhang, Chai, Chen, Ren, Gong (CR35) 2014; 35 Holler, Zaru, Micheau, Thome, Attinger, Valitutti (CR51) 2000; 1 Zhao, Cai, Yang, Qiu, Liao, Li (CR17) 2013; 8 Dohi, Yasui, Gen, Takada, Endo, Tsuji (CR26) 2013; 42 Tam, Ben-Yehuda, Hayward (CR38) 1997; 17 Geller, Gorlick (CR2) 2010; 8 Li, Hassan, Volinia, van Wijnen, Stein, Croce (CR8) 2008; 105 Kansara, Thomas (CR41) 2007; 26 Ofengeim, Yuan (CR47) 2013; 14 Kim, Ohoka, Okuhira, Sai, Nishimaki-Mogami, Naito (CR46) 2010; 101 Wang, Zhao, Fu (CR22) 2013; 384 Yuan, Ossendorf, Szatkowski, Bronk, Maran, Yaszemski (CR18) 2009; 27 Sun, Song, Wang, Wang, Gao, Chen (CR24) 2014; 7 Zhu, Xia, Zuo, Jin, Zhou, Yao (CR25) 2012; 29 Jones, Salah, Del Mare, Galasso, Gaudio, Nuovo (CR10) 2012; 72 Yang, Gao, Tang, Cai, Lin, Fu (CR16) 2013; 381 Lauvrak, Munthe, Kresse, Stratford, Namlos, Meza-Zepeda (CR36) 2013; 109 Sarver, Thayanithy, Scott, Cleton-Jansen, Hogendoorn, Modiano (CR12) 2013; 8 17911593 - J Immunol. 2007 Oct 15;179(8):5082-9 25409146 - Nature. 2015 Feb 5;518(7537):107-10 18238902 - Proc Natl Acad Sci U S A. 2008 Feb 12;105(6):1949-54 24129419 - Nat Rev Mol Cell Biol. 2013 Nov;14(11):727-36 11821461 - J Clin Oncol. 2002 Feb 1;20(3):776-90 26344099 - Mol Cell. 2015 Oct 1;60(1):63-76 12456778 - Mol Pathol. 2002 Dec;55(6):389-93 23486187 - Bone. 2013 Jul;55(1):166-78 23534542 - N Engl J Med. 2013 May 2;368(18):1685-94 23162647 - Oncol Lett. 2012 Nov;4(5):1037-1042 24920927 - Onco Targets Ther. 2014 May 28;7:853-63 23975506 - Mol Cell Biochem. 2013 Dec;384(1-2):105-11 12938165 - J Cell Biochem. 2003 Sep 1;90(1):158-69 11101870 - Nat Immunol. 2000 Dec;1(6):489-95 21994419 - Clin Cancer Res. 2011 Dec 15;17 (24):7574-83 7538908 - Cell. 1995 May 19;81(4):513-23 20949564 - Int J Cancer. 2011 Aug 1;129(3):680-90 22167392 - Med Oncol. 2012 Dec;29(4):2701-9 23670799 - Mol Cell Biochem. 2013 Aug;380(1-2):277-82 18784367 - Proc Natl Acad Sci U S A. 2008 Sep 16;105(37):13906-11 19197972 - Cancer. 2009 Apr 1;115(7):1531-43 22797073 - Oncogene. 2013 Jun 13;32(24):2992-3000 23874105 - Onco Targets Ther. 2013 Jul 08;6:833-8 21605702 - J Biomed Inform. 2011 Oct;44(5):839-47 18539114 - Dev Cell. 2008 Jun;14(6):843-53 10642801 - Dev Biol. 1999 Dec 15;216(2):671-80 14744438 - Cell. 2004 Jan 23;116(2):281-97 17301840 - Cell Death Differ. 2007 Mar;14 (3):400-10 25289062 - Exp Ther Med. 2014 Nov;8(5):1575-1580 21289068 - Genes Dev. 2011 Feb 1;25(3):226-31 3170025 - Int J Cancer. 1988 Oct 15;42(4):511-20 18628472 - Clin Cancer Res. 2008 Jul 15;14(14):4572-83 23569431 - Int J Med Sci. 2013;10(6):676-82 22350417 - Cancer Res. 2012 Apr 1;72(7):1865-77 9032277 - Mol Cell Biol. 1997 Mar;17(3):1490-502 23339462 - Genome Med. 2013 Jan 22;5(1):2 26000607 - PLoS One. 2015 May 22;10 (5):e0127386 23311495 - Orphanet J Rare Dis. 2013 Jan 11;8:7 23229728 - Int J Oncol. 2013 Feb;42(2):411-8 25185654 - Tumour Biol. 2014 Dec;35(12):12467-72 22814620 - Cell Death Differ. 2012 Dec;19(12 ):2003-14 19724913 - Int J Oncol. 2009 Oct;35(4):775-88 18485876 - Cell. 2008 May 16;133(4):693-703 8855284 - Proc Natl Acad Sci U S A. 1996 Oct 1;93(20):10923-7 24064976 - Br J Cancer. 2013 Oct 15;109(8):2228-36 18559481 - Genes Dev. 2008 Jun 15;22(12):1662-76 19933329 - Proc Natl Acad Sci U S A. 2009 Dec 8;106(49):20794-9 17066459 - Pediatr Blood Cancer. 2007 Dec;49(7):928-40 23801049 - Mol Cell Biochem. 2013 Sep;381(1-2):9-15 22685206 - Proc Natl Acad Sci U S A. 2012 Jun 26;109(26):E1695-704 19212826 - Cancer Invest. 2009 May;27(4):435-42 17263592 - DNA Cell Biol. 2007 Jan;26(1):1-18 21317869 - Clin Adv Hematol Oncol. 2010 Oct;8(10):705-18 23372675 - PLoS One. 2013;8(1):e53906 20431052 - Clin Chem. 2010 Jul;56(7):1107-18 20825417 - Cancer Sci. 2010 Nov;101(11):2425-9 12398939 - Bone. 2002 Oct;31(4):448-56 JR Batanian (BFonc201668_CR40) 2002; 55 J Yang (BFonc201668_CR16) 2013; 381 H Lv (BFonc201668_CR37) 2014; 8 PH Olsen (BFonc201668_CR6) 1999; 216 N Festjens (BFonc201668_CR43) 2007; 14 PJ Houghton (BFonc201668_CR56) 2007; 49 J Sun (BFonc201668_CR24) 2014; 7 SU Lauvrak (BFonc201668_CR36) 2013; 109 BZ Stanger (BFonc201668_CR44) 1995; 81 L Wang (BFonc201668_CR45) 2008; 133 J Lu (BFonc201668_CR57) 2008; 14 Y Wang (BFonc201668_CR22) 2013; 384 B Zheng (BFonc201668_CR34) 2011; 17 L Mirabello (BFonc201668_CR4) 2009; 115 A Gougelet (BFonc201668_CR14) 2011; 129 H Dweep (BFonc201668_CR28) 2011; 44 H Hu (BFonc201668_CR13) 2012; 4 O Dohi (BFonc201668_CR26) 2013; 42 KB Jones (BFonc201668_CR10) 2012; 72 E Tili (BFonc201668_CR30) 2007; 179 AL Sarver (BFonc201668_CR12) 2013; 8 G Neale (BFonc201668_CR31) 2008; 14 H Inose (BFonc201668_CR9) 2009; 106 T Kobayashi (BFonc201668_CR7) 2008; 105 CC Yen (BFonc201668_CR39) 2009; 35 M Kansara (BFonc201668_CR41) 2007; 26 CJ Cheng (BFonc201668_CR52) 2015; 518 EH Allan (BFonc201668_CR21) 2003; 90 J Yuan (BFonc201668_CR18) 2009; 27 D Ofengeim (BFonc201668_CR47) 2013; 14 M Zhang (BFonc201668_CR49) 2015; 10 GJ Atkins (BFonc201668_CR55) 2002; 31 DM Parkin (BFonc201668_CR1) 1988; 42 G Zhao (BFonc201668_CR17) 2013; 8 W Ma (BFonc201668_CR35) 2014; 35 N Holler (BFonc201668_CR51) 2000; 1 S Kim (BFonc201668_CR46) 2010; 101 PM Neilsen (BFonc201668_CR29) 2013; 32 Y Dondelinger (BFonc201668_CR50) 2015; 60 Z Li (BFonc201668_CR8) 2008; 105 X Wu (BFonc201668_CR11) 2013; 10 N Hanoun (BFonc201668_CR23) 2010; 56 CR Walkley (BFonc201668_CR19) 2008; 22 DS Geller (BFonc201668_CR2) 2010; 8 S Grimm (BFonc201668_CR42) 1996; 93 S Jouan-Lanhouet (BFonc201668_CR48) 2012; 19 A Zhu (BFonc201668_CR25) 2012; 29 SS Bielack (BFonc201668_CR3) 2002; 20 HL Janssen (BFonc201668_CR54) 2013; 368 AJ Mutsaers (BFonc201668_CR20) 2013; 55 J Li (BFonc201668_CR33) 2013; 380 KJ Png (BFonc201668_CR27) 2011; 25 IA Babar (BFonc201668_CR53) 2012; 109 W Tam (BFonc201668_CR38) 1997; 17 DP Bartel (BFonc201668_CR5) 2004; 116 AD Kelly (BFonc201668_CR32) 2013; 5 M Tang (BFonc201668_CR15) 2013; 6 |
References_xml | – volume: 7 start-page: 853 year: 2014 end-page: 863 ident: CR24 article-title: Clinical significance of promoter region hypermethylation of microRNA-148a in gastrointestinal cancers publication-title: Onco Targets Ther contributor: fullname: Chen – volume: 1 start-page: 489 year: 2000 end-page: 495 ident: CR51 article-title: Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule publication-title: Nat Immunol doi: 10.1038/82732 contributor: fullname: Valitutti – volume: 518 start-page: 107 year: 2015 end-page: 110 ident: CR52 article-title: MicroRNA silencing for cancer therapy targeted to the tumour microenvironment publication-title: Nature doi: 10.1038/nature13905 contributor: fullname: Liu – volume: 17 start-page: 7574 year: 2011 end-page: 7583 ident: CR34 article-title: MicroRNA-148a suppresses tumor cell invasion and metastasis by downregulating ROCK1 in gastric cancer publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-11-1714 contributor: fullname: Zha – volume: 4 start-page: 1037 year: 2012 end-page: 1042 ident: CR13 article-title: Changes in microRNA expression in the MG-63 osteosarcoma cell line compared with osteoblasts publication-title: Oncol Lett doi: 10.3892/ol.2012.866 contributor: fullname: Cai – volume: 42 start-page: 511 year: 1988 end-page: 520 ident: CR1 article-title: The international incidence of childhood cancer publication-title: Int J Cancer doi: 10.1002/ijc.2910420408 contributor: fullname: Bieber – volume: 8 start-page: 705 year: 2010 end-page: 718 ident: CR2 article-title: Osteosarcoma: a review of diagnosis, management, and treatment strategies publication-title: Clin Adv Hematol Oncol contributor: fullname: Gorlick – volume: 14 start-page: 727 year: 2013 end-page: 736 ident: CR47 article-title: Regulation of RIP1 kinase signalling at the crossroads of inflammation and cell death publication-title: Nat Rev Mol Cell Biol doi: 10.1038/nrm3683 contributor: fullname: Yuan – volume: 5 start-page: 2 year: 2013 ident: CR32 article-title: MicroRNA paraffin-based studies in osteosarcoma reveal reproducible independent prognostic profiles at 14q32 publication-title: Genome Med doi: 10.1186/gm406 contributor: fullname: Goldsmith – volume: 384 start-page: 105 year: 2013 end-page: 111 ident: CR22 article-title: miR-335 suppresses migration and invasion by targeting ROCK1 in osteosarcoma cells publication-title: Mol Cell Biochem doi: 10.1007/s11010-013-1786-4 contributor: fullname: Fu – volume: 60 start-page: 63 year: 2015 end-page: 76 ident: CR50 article-title: NF-kappaB-independent role of IKKalpha/IKKbeta in preventing RIPK1 kinase-dependent apoptotic and necroptotic cell death during tnf signaling publication-title: Mol Cell. doi: 10.1016/j.molcel.2015.07.032 contributor: fullname: Gough – volume: 105 start-page: 13906 year: 2008 end-page: 13911 ident: CR8 article-title: A microRNA signature for a BMP2-induced osteoblast lineage commitment program publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.0804438105 contributor: fullname: Croce – volume: 32 start-page: 2992 year: 2013 end-page: 3000 ident: CR29 article-title: Mutant p53 drives invasion in breast tumors through up-regulation of miR-155 publication-title: Oncogene doi: 10.1038/onc.2012.305 contributor: fullname: Schulz – volume: 101 start-page: 2425 year: 2010 end-page: 2429 ident: CR46 article-title: Modulation of RIP1 ubiquitylation and distribution by MeBS to sensitize cancer cells to tumor necrosis factor alpha-induced apoptosis publication-title: Cancer Sci doi: 10.1111/j.1349-7006.2010.01697.x contributor: fullname: Naito – volume: 8 start-page: 1575 year: 2014 end-page: 1580 ident: CR37 article-title: inhibitor reduces the proliferation and migration in osteosarcoma MG-63 cells publication-title: Exp Ther Med doi: 10.3892/etm.2014.1942 contributor: fullname: Jiang – volume: 109 start-page: E1695 year: 2012 end-page: E1704 ident: CR53 article-title: Nanoparticle-based therapy in an microRNA-155 (miR-155)-dependent mouse model of lymphoma publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.1201516109 contributor: fullname: Saltzman – volume: 56 start-page: 1107 year: 2010 end-page: 1118 ident: CR23 article-title: The silencing of microRNA 148a production by DNA hypermethylation is an early event in pancreatic carcinogenesis publication-title: Clin Chem doi: 10.1373/clinchem.2010.144709 contributor: fullname: Selves – volume: 129 start-page: 680 year: 2011 end-page: 690 ident: CR14 article-title: Micro-RNA profiles in osteosarcoma as a predictive tool for ifosfamide response publication-title: Int J Cancer doi: 10.1002/ijc.25715 contributor: fullname: Dutour – volume: 44 start-page: 839 year: 2011 end-page: 847 ident: CR28 article-title: miRWalk—database: prediction of possible miRNA binding sites by "walking" the genes of three genomes publication-title: J Biomed Inform doi: 10.1016/j.jbi.2011.05.002 contributor: fullname: Gretz – volume: 19 start-page: 2003 year: 2012 end-page: 2014 ident: CR48 article-title: TRAIL induces necroptosis involving RIPK1/RIPK3-dependent PARP-1 activation publication-title: Cell Death Differ doi: 10.1038/cdd.2012.90 contributor: fullname: Van Herreweghe – volume: 115 start-page: 1531 year: 2009 end-page: 1543 ident: CR4 article-title: Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program publication-title: Cancer doi: 10.1002/cncr.24121 contributor: fullname: Savage – volume: 10 start-page: e0127386 year: 2015 ident: CR49 article-title: The Roles of ROS and Caspases in TRAIL-Induced Apoptosis and Necroptosis in Human Pancreatic Cancer Cells publication-title: PLoS One doi: 10.1371/journal.pone.0127386 contributor: fullname: Harada – volume: 42 start-page: 411 year: 2013 end-page: 418 ident: CR26 article-title: Epigenetic silencing of miR-335 and its host gene MEST in hepatocellular carcinoma publication-title: Int J Oncol doi: 10.3892/ijo.2012.1724 contributor: fullname: Tsuji – volume: 55 start-page: 389 year: 2002 end-page: 393 ident: CR40 article-title: Evaluation of paediatric osteosarcomas by classic cytogenetic and CGH analyses publication-title: Mol Pathol doi: 10.1136/mp.55.6.389 contributor: fullname: Ramos – volume: 179 start-page: 5082 year: 2007 end-page: 5089 ident: CR30 article-title: Modulation of miR-155 and miR-125b levels following lipopolysaccharide/TNF-alpha stimulation and their possible roles in regulating the response to endotoxin shock publication-title: J Immunol doi: 10.4049/jimmunol.179.8.5082 contributor: fullname: Adair – volume: 116 start-page: 281 year: 2004 end-page: 297 ident: CR5 article-title: MicroRNAs: genomics, biogenesis, mechanism, and function publication-title: Cell doi: 10.1016/S0092-8674(04)00045-5 contributor: fullname: Bartel – volume: 216 start-page: 671 year: 1999 end-page: 680 ident: CR6 article-title: The lin-4 regulatory RNA controls developmental timing in Caenorhabditis elegans by blocking LIN-14 protein synthesis after the initiation of translation publication-title: Dev Biol doi: 10.1006/dbio.1999.9523 contributor: fullname: Ambros – volume: 17 start-page: 1490 year: 1997 end-page: 1502 ident: CR38 article-title: bic, a novel gene activated by proviral insertions in avian leukosis virus-induced lymphomas, is likely to function through its noncoding RNA publication-title: Mol Cell Biol doi: 10.1128/MCB.17.3.1490 contributor: fullname: Hayward – volume: 10 start-page: 676 year: 2013 end-page: 682 ident: CR11 article-title: MicroRNA-34a inhibits human osteosarcoma proliferation by downregulating ether a go-go 1 expression publication-title: Int J Med Sci doi: 10.7150/ijms.5528 contributor: fullname: Wu – volume: 14 start-page: 843 year: 2008 end-page: 853 ident: CR57 article-title: MicroRNA-mediated control of cell fate in megakaryocyte-erythrocyte progenitors publication-title: Dev Cell doi: 10.1016/j.devcel.2008.03.012 contributor: fullname: Bosco – volume: 14 start-page: 400 year: 2007 end-page: 410 ident: CR43 article-title: RIP1, a kinase on the crossroads of a cell's decision to live or die publication-title: Cell Death Differ doi: 10.1038/sj.cdd.4402085 contributor: fullname: Vandenabeele – volume: 380 start-page: 277 year: 2013 end-page: 282 ident: CR33 article-title: MicroRNA-148a suppresses epithelial-to-mesenchymal transition by targeting ROCK1 in non-small cell lung cancer cells publication-title: Mol Cell Biochem doi: 10.1007/s11010-013-1682-y contributor: fullname: Yu – volume: 20 start-page: 776 year: 2002 end-page: 790 ident: CR3 article-title: Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols publication-title: J Clin Oncol doi: 10.1200/JCO.2002.20.3.776 contributor: fullname: Helmke – volume: 106 start-page: 20794 year: 2009 end-page: 20799 ident: CR9 article-title: A microRNA regulatory mechanism of osteoblast differentiation publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.0909311106 contributor: fullname: Sato – volume: 381 start-page: 9 year: 2013 end-page: 15 ident: CR16 article-title: Loss of microRNA-132 predicts poor prognosis in patients with primary osteosarcoma publication-title: Mol Cell Biochem doi: 10.1007/s11010-013-1677-8 contributor: fullname: Fu – volume: 55 start-page: 166 year: 2013 end-page: 178 ident: CR20 article-title: Modeling distinct osteosarcoma subtypes using Cre:lox and lineage-restricted transgenic shRNA publication-title: Bone doi: 10.1016/j.bone.2013.02.016 contributor: fullname: Wall – volume: 26 start-page: 1 year: 2007 end-page: 18 ident: CR41 article-title: Molecular pathogenesis of osteosarcoma publication-title: DNA Cell Biol doi: 10.1089/dna.2006.0505 contributor: fullname: Thomas – volume: 8 start-page: 7 year: 2013 ident: CR12 article-title: MicroRNAs at the human 14q32 locus have prognostic significance in osteosarcoma publication-title: Orphanet J Rare Dis doi: 10.1186/1750-1172-8-7 contributor: fullname: Modiano – volume: 27 start-page: 435 year: 2009 end-page: 442 ident: CR18 article-title: Osteoblastic and osteolytic human osteosarcomas can be studied with a new xenograft mouse model producing spontaneous metastases publication-title: Cancer Invest doi: 10.1080/07357900802491477 contributor: fullname: Yaszemski – volume: 49 start-page: 928 year: 2007 end-page: 940 ident: CR56 article-title: The pediatric preclinical testing program: description of models and early testing results publication-title: Pediatr Blood Cancer doi: 10.1002/pbc.21078 contributor: fullname: Cole – volume: 25 start-page: 226 year: 2011 end-page: 231 ident: CR27 article-title: MicroRNA-335 inhibits tumor reinitiation and is silenced through genetic and epigenetic mechanisms in human breast cancer publication-title: Genes Dev doi: 10.1101/gad.1974211 contributor: fullname: Rimner – volume: 29 start-page: 2701 year: 2012 end-page: 2709 ident: CR25 article-title: MicroRNA-148a is silenced by hypermethylation and interacts with DNA methyltransferase 1 in gastric cancer publication-title: Med Oncol doi: 10.1007/s12032-011-0134-3 contributor: fullname: Yao – volume: 133 start-page: 693 year: 2008 end-page: 703 ident: CR45 article-title: TNF-alpha induces two distinct caspase-8 activation pathways publication-title: Cell doi: 10.1016/j.cell.2008.03.036 contributor: fullname: Wang – volume: 31 start-page: 448 year: 2002 end-page: 456 ident: CR55 article-title: Human osteoblasts are resistant to Apo2L/TRAIL-mediated apoptosis publication-title: Bone doi: 10.1016/S8756-3282(02)00858-X contributor: fullname: Zannettino – volume: 14 start-page: 4572 year: 2008 end-page: 4583 ident: CR31 article-title: Molecular characterization of the pediatric preclinical testing panel publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-07-5090 contributor: fullname: Lock – volume: 368 start-page: 1685 year: 2013 end-page: 1694 ident: CR54 article-title: Treatment of HCV infection by targeting microRNA publication-title: N Engl J Med doi: 10.1056/NEJMoa1209026 contributor: fullname: Patel – volume: 93 start-page: 10923 year: 1996 end-page: 10927 ident: CR42 article-title: RIP and FADD: two "death domain"-containing proteins can induce apoptosis by convergent, but dissociable, pathways publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.93.20.10923 contributor: fullname: Leder – volume: 105 start-page: 1949 year: 2008 end-page: 1954 ident: CR7 article-title: Dicer-dependent pathways regulate chondrocyte proliferation and differentiation publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.0707900105 contributor: fullname: Schipani – volume: 90 start-page: 158 year: 2003 end-page: 169 ident: CR21 article-title: Differentiation potential of a mouse bone marrow stromal cell line publication-title: J Cell Biochem doi: 10.1002/jcb.10614 contributor: fullname: Gillespie – volume: 81 start-page: 513 year: 1995 end-page: 523 ident: CR44 article-title: RIP: a novel protein containing a death domain that interacts with Fas/APO-1 (CD95) in yeast and causes cell death publication-title: Cell doi: 10.1016/0092-8674(95)90072-1 contributor: fullname: Seed – volume: 109 start-page: 2228 year: 2013 end-page: 2236 ident: CR36 article-title: Functional characterisation of osteosarcoma cell lines and identification of mRNAs and miRNAs associated with aggressive cancer phenotypes publication-title: Br J Cancer doi: 10.1038/bjc.2013.549 contributor: fullname: Meza-Zepeda – volume: 6 start-page: 833 year: 2013 end-page: 838 ident: CR15 article-title: MicroRNA-145 downregulation associates with advanced tumor progression and poor prognosis in patients suffering osteosarcoma publication-title: Onco Targets Ther contributor: fullname: Zhou – volume: 35 start-page: 775 year: 2009 end-page: 788 ident: CR39 article-title: Identification of chromosomal aberrations associated with disease progression and a novel 3q13.31 deletion involving LSAMP gene in osteosarcoma publication-title: Int J Oncol contributor: fullname: Chiou – volume: 72 start-page: 1865 year: 2012 end-page: 1877 ident: CR10 article-title: miRNA signatures associate with pathogenesis and progression of osteosarcoma publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-11-2663 contributor: fullname: Nuovo – volume: 35 start-page: 12467 year: 2014 end-page: 12472 ident: CR35 article-title: Circulating miR-148a is a significant diagnostic and prognostic biomarker for patients with osteosarcoma publication-title: Tumour Biol doi: 10.1007/s13277-014-2565-x contributor: fullname: Gong – volume: 22 start-page: 1662 year: 2008 end-page: 1676 ident: CR19 article-title: Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease publication-title: Genes Dev doi: 10.1101/gad.1656808 contributor: fullname: Roth – volume: 8 start-page: e53906 year: 2013 ident: CR17 article-title: MicroRNA-221 induces cell survival and cisplatin resistance through PI3K/Akt pathway in human osteosarcoma publication-title: PLoS One doi: 10.1371/journal.pone.0053906 contributor: fullname: Li – volume: 81 start-page: 513 year: 1995 ident: BFonc201668_CR44 publication-title: Cell doi: 10.1016/0092-8674(95)90072-1 contributor: fullname: BZ Stanger – volume: 22 start-page: 1662 year: 2008 ident: BFonc201668_CR19 publication-title: Genes Dev doi: 10.1101/gad.1656808 contributor: fullname: CR Walkley – volume: 31 start-page: 448 year: 2002 ident: BFonc201668_CR55 publication-title: Bone doi: 10.1016/S8756-3282(02)00858-X contributor: fullname: GJ Atkins – volume: 216 start-page: 671 year: 1999 ident: BFonc201668_CR6 publication-title: Dev Biol doi: 10.1006/dbio.1999.9523 contributor: fullname: PH Olsen – volume: 6 start-page: 833 year: 2013 ident: BFonc201668_CR15 publication-title: Onco Targets Ther contributor: fullname: M Tang – volume: 35 start-page: 12467 year: 2014 ident: BFonc201668_CR35 publication-title: Tumour Biol doi: 10.1007/s13277-014-2565-x contributor: fullname: W Ma – volume: 14 start-page: 400 year: 2007 ident: BFonc201668_CR43 publication-title: Cell Death Differ doi: 10.1038/sj.cdd.4402085 contributor: fullname: N Festjens – volume: 380 start-page: 277 year: 2013 ident: BFonc201668_CR33 publication-title: Mol Cell Biochem doi: 10.1007/s11010-013-1682-y contributor: fullname: J Li – volume: 8 start-page: 705 year: 2010 ident: BFonc201668_CR2 publication-title: Clin Adv Hematol Oncol contributor: fullname: DS Geller – volume: 368 start-page: 1685 year: 2013 ident: BFonc201668_CR54 publication-title: N Engl J Med doi: 10.1056/NEJMoa1209026 contributor: fullname: HL Janssen – volume: 5 start-page: 2 year: 2013 ident: BFonc201668_CR32 publication-title: Genome Med doi: 10.1186/gm406 contributor: fullname: AD Kelly – volume: 25 start-page: 226 year: 2011 ident: BFonc201668_CR27 publication-title: Genes Dev doi: 10.1101/gad.1974211 contributor: fullname: KJ Png – volume: 109 start-page: E1695 year: 2012 ident: BFonc201668_CR53 publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.1201516109 contributor: fullname: IA Babar – volume: 42 start-page: 411 year: 2013 ident: BFonc201668_CR26 publication-title: Int J Oncol doi: 10.3892/ijo.2012.1724 contributor: fullname: O Dohi – volume: 101 start-page: 2425 year: 2010 ident: BFonc201668_CR46 publication-title: Cancer Sci doi: 10.1111/j.1349-7006.2010.01697.x contributor: fullname: S Kim – volume: 19 start-page: 2003 year: 2012 ident: BFonc201668_CR48 publication-title: Cell Death Differ doi: 10.1038/cdd.2012.90 contributor: fullname: S Jouan-Lanhouet – volume: 8 start-page: e53906 year: 2013 ident: BFonc201668_CR17 publication-title: PLoS One doi: 10.1371/journal.pone.0053906 contributor: fullname: G Zhao – volume: 179 start-page: 5082 year: 2007 ident: BFonc201668_CR30 publication-title: J Immunol doi: 10.4049/jimmunol.179.8.5082 contributor: fullname: E Tili – volume: 115 start-page: 1531 year: 2009 ident: BFonc201668_CR4 publication-title: Cancer doi: 10.1002/cncr.24121 contributor: fullname: L Mirabello – volume: 10 start-page: 676 year: 2013 ident: BFonc201668_CR11 publication-title: Int J Med Sci doi: 10.7150/ijms.5528 contributor: fullname: X Wu – volume: 14 start-page: 4572 year: 2008 ident: BFonc201668_CR31 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-07-5090 contributor: fullname: G Neale – volume: 49 start-page: 928 year: 2007 ident: BFonc201668_CR56 publication-title: Pediatr Blood Cancer doi: 10.1002/pbc.21078 contributor: fullname: PJ Houghton – volume: 381 start-page: 9 year: 2013 ident: BFonc201668_CR16 publication-title: Mol Cell Biochem doi: 10.1007/s11010-013-1677-8 contributor: fullname: J Yang – volume: 116 start-page: 281 year: 2004 ident: BFonc201668_CR5 publication-title: Cell doi: 10.1016/S0092-8674(04)00045-5 contributor: fullname: DP Bartel – volume: 55 start-page: 389 year: 2002 ident: BFonc201668_CR40 publication-title: Mol Pathol doi: 10.1136/mp.55.6.389 contributor: fullname: JR Batanian – volume: 1 start-page: 489 year: 2000 ident: BFonc201668_CR51 publication-title: Nat Immunol doi: 10.1038/82732 contributor: fullname: N Holler – volume: 72 start-page: 1865 year: 2012 ident: BFonc201668_CR10 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-11-2663 contributor: fullname: KB Jones – volume: 10 start-page: e0127386 year: 2015 ident: BFonc201668_CR49 publication-title: PLoS One doi: 10.1371/journal.pone.0127386 contributor: fullname: M Zhang – volume: 27 start-page: 435 year: 2009 ident: BFonc201668_CR18 publication-title: Cancer Invest doi: 10.1080/07357900802491477 contributor: fullname: J Yuan – volume: 4 start-page: 1037 year: 2012 ident: BFonc201668_CR13 publication-title: Oncol Lett doi: 10.3892/ol.2012.866 contributor: fullname: H Hu – volume: 93 start-page: 10923 year: 1996 ident: BFonc201668_CR42 publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.93.20.10923 contributor: fullname: S Grimm – volume: 55 start-page: 166 year: 2013 ident: BFonc201668_CR20 publication-title: Bone doi: 10.1016/j.bone.2013.02.016 contributor: fullname: AJ Mutsaers – volume: 26 start-page: 1 year: 2007 ident: BFonc201668_CR41 publication-title: DNA Cell Biol doi: 10.1089/dna.2006.0505 contributor: fullname: M Kansara – volume: 105 start-page: 1949 year: 2008 ident: BFonc201668_CR7 publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.0707900105 contributor: fullname: T Kobayashi – volume: 109 start-page: 2228 year: 2013 ident: BFonc201668_CR36 publication-title: Br J Cancer doi: 10.1038/bjc.2013.549 contributor: fullname: SU Lauvrak – volume: 20 start-page: 776 year: 2002 ident: BFonc201668_CR3 publication-title: J Clin Oncol doi: 10.1200/JCO.2002.20.3.776 contributor: fullname: SS Bielack – volume: 17 start-page: 7574 year: 2011 ident: BFonc201668_CR34 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-11-1714 contributor: fullname: B Zheng – volume: 106 start-page: 20794 year: 2009 ident: BFonc201668_CR9 publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.0909311106 contributor: fullname: H Inose – volume: 32 start-page: 2992 year: 2013 ident: BFonc201668_CR29 publication-title: Oncogene doi: 10.1038/onc.2012.305 contributor: fullname: PM Neilsen – volume: 384 start-page: 105 year: 2013 ident: BFonc201668_CR22 publication-title: Mol Cell Biochem doi: 10.1007/s11010-013-1786-4 contributor: fullname: Y Wang – volume: 29 start-page: 2701 year: 2012 ident: BFonc201668_CR25 publication-title: Med Oncol doi: 10.1007/s12032-011-0134-3 contributor: fullname: A Zhu – volume: 42 start-page: 511 year: 1988 ident: BFonc201668_CR1 publication-title: Int J Cancer doi: 10.1002/ijc.2910420408 contributor: fullname: DM Parkin – volume: 8 start-page: 1575 year: 2014 ident: BFonc201668_CR37 publication-title: Exp Ther Med doi: 10.3892/etm.2014.1942 contributor: fullname: H Lv – volume: 518 start-page: 107 year: 2015 ident: BFonc201668_CR52 publication-title: Nature doi: 10.1038/nature13905 contributor: fullname: CJ Cheng – volume: 133 start-page: 693 year: 2008 ident: BFonc201668_CR45 publication-title: Cell doi: 10.1016/j.cell.2008.03.036 contributor: fullname: L Wang – volume: 105 start-page: 13906 year: 2008 ident: BFonc201668_CR8 publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.0804438105 contributor: fullname: Z Li – volume: 14 start-page: 843 year: 2008 ident: BFonc201668_CR57 publication-title: Dev Cell doi: 10.1016/j.devcel.2008.03.012 contributor: fullname: J Lu – volume: 7 start-page: 853 year: 2014 ident: BFonc201668_CR24 publication-title: Onco Targets Ther contributor: fullname: J Sun – volume: 8 start-page: 7 year: 2013 ident: BFonc201668_CR12 publication-title: Orphanet J Rare Dis doi: 10.1186/1750-1172-8-7 contributor: fullname: AL Sarver – volume: 56 start-page: 1107 year: 2010 ident: BFonc201668_CR23 publication-title: Clin Chem doi: 10.1373/clinchem.2010.144709 contributor: fullname: N Hanoun – volume: 44 start-page: 839 year: 2011 ident: BFonc201668_CR28 publication-title: J Biomed Inform doi: 10.1016/j.jbi.2011.05.002 contributor: fullname: H Dweep – volume: 60 start-page: 63 year: 2015 ident: BFonc201668_CR50 publication-title: Mol Cell. doi: 10.1016/j.molcel.2015.07.032 contributor: fullname: Y Dondelinger – volume: 17 start-page: 1490 year: 1997 ident: BFonc201668_CR38 publication-title: Mol Cell Biol doi: 10.1128/MCB.17.3.1490 contributor: fullname: W Tam – volume: 90 start-page: 158 year: 2003 ident: BFonc201668_CR21 publication-title: J Cell Biochem doi: 10.1002/jcb.10614 contributor: fullname: EH Allan – volume: 35 start-page: 775 year: 2009 ident: BFonc201668_CR39 publication-title: Int J Oncol contributor: fullname: CC Yen – volume: 129 start-page: 680 year: 2011 ident: BFonc201668_CR14 publication-title: Int J Cancer doi: 10.1002/ijc.25715 contributor: fullname: A Gougelet – volume: 14 start-page: 727 year: 2013 ident: BFonc201668_CR47 publication-title: Nat Rev Mol Cell Biol doi: 10.1038/nrm3683 contributor: fullname: D Ofengeim |
SSID | ssj0007902 |
Score | 2.5038416 |
Snippet | Osteosarcoma (OS) is the most common cancer of bone and the 5th leading cause of cancer-related death in young adults. Currently, 5-year survival rates have... |
SourceID | proquest gale crossref pubmed springer |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 5282 |
SubjectTerms | 13/2 13/31 13/89 38/39 38/90 631/67/1798 64/60 82/80 Analysis Animal models Animals Apoptosis Apoptosis - genetics Biochemistry Bone cancer Cell Biology Cell death Cell Differentiation - genetics Cell fate Cell Line, Tumor Cell proliferation Cell Proliferation - genetics Computer applications Disease Models, Animal Gene Expression Regulation, Neoplastic Genetic engineering Genetically modified organisms Human Genetics Humans Internal Medicine Medicine Medicine & Public Health Metastases Mice MicroRNA MicroRNAs MicroRNAs - biosynthesis MicroRNAs - genetics miRNA Necroptosis Oncology original-article Osteoblasts Osteosarcoma Osteosarcoma - genetics Osteosarcoma - pathology Protein-serine/threonine kinase Receptor-Interacting Protein Serine-Threonine Kinases - genetics Sarcoma siRNA Tumor cells Wildlife conservation Young adults |
Title | Increased miR-155-5p and reduced miR-148a-3p contribute to the suppression of osteosarcoma cell death |
URI | https://link.springer.com/article/10.1038/onc.2016.68 https://www.ncbi.nlm.nih.gov/pubmed/27041566 https://www.proquest.com/docview/1826237742 https://www.proquest.com/docview/2641591806 https://search.proquest.com/docview/1837309720 |
Volume | 35 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwEB7RVlAuCJZXoKyMVMTJNHFsxzmhsmpVIbVCVZH2Fjl-SByahN3sof8eT-K024K4RbHlxB575hvPC-BQMlNz4RhlzNeUB_hGa5dxyqXJ61pKJQsMTj6_kGc_-felWMYLt3V0q5x44sCobWvwjvwoCO4geTOVyq_db4pVo9C6Gkto7MBehoIOI8UXdy4exehzGFBESgOQYTE-L83VUdtg_sJMfsEcq1sS6SFf3hJMDyylgwA6fQ7PInIkxyOpX8Aj18zg8VhL8mYG-4updNsMnpxHi_lLcIEBoN-5s-T61yUNcp2KjujGkhUmbZ1ec6Vp3pHBcR0rYDnStyRgQ7LedNFVtiGtJxgS0q7D4WivNcFLf2IRQ76Cq9OTq8UZjaUVqAn6QU-914FC2ivhbZZ5VVqXB2VGOmtMZkurcy5q6a3jOSpwGvUWVltjs7LA59ew27SNewtE-UxJLXShreFcl0qkOJ6ohVXMC5PA4bS6VTcm0KgGw3euqkCEColQSZXAZ1z5Co9Vv9JGx-iA8BFMUFUdY163oDwKlsDBvZ5hac395ol2VTyO6wqVKJYHpPvv5ru9lcDH22YcGD3QGtducIg8MMOyYGkCb8YtcTsfVqSDHpzAp2mPbH3778m--_9PvIen2HFwGZQHsNuvNu5DgD59PYedYlnMh10-h71vJxc_Lv8AmXsAhQ |
link.rule.ids | 314,780,784,12056,12223,21388,27924,27925,31719,31720,33266,33267,33744,33745,43310,43579,43805,73745,74014,74302 |
linkProvider | ProQuest |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwEB7BVlAuCJZXoICRiji5TRzbcU6oVK0W6K5QtUi9RY7tSByahN3sgX-PJ3GWbUHcojhxYo89843nBXAomSm5cIwyVpWUe_hGS5dwyqVJy1JKJTMMTp4v5Ow7_3IlrsKB2zq4VY48sWfUtjF4Rn7sBbeXvImK5cf2J8WqUWhdDSU07sIeZk4XE9j7dLb4drnlxdngdehxREw9lGEhQi9O1XFTYwbDRB5hltUdmXSbM--Iplu20l4EnT-ChwE7kpOB2I_hjquncG-oJvlrCvunY_G2KdyfB5v5E3CeBaDnubPk-scl9ZKdipbo2pIVpm0db3OladqS3nUda2A50jXEo0Oy3rTBWbYmTUUwKKRZ--3RXGuCx_7EIop8Csvzs-XpjIbiCtR4DaGjVaU9jXSlRGWTpFK5dalXZ6SzxiQ2tzrlopSVdTxFFU6j5sJKa2ySZ3j9DCZ1U7sXQFSVKKmFzrQ1nOtciRj7E6WwilXCRHA4zm7RDik0it70narCE6FAIhRSRfABZ77AjdWttNEhPsB_BFNUFSeY2c2rj4JFcHDjST-15mbzSLsibMh1gWoUSz3W_Xfzn9UVwbttM3aMPmi1azbYRerZYZ6xOILnw5LYjodlca8JR_B-XCM73_57sC___xNvYX-2nF8UF58XX1_BA3ypdyCUBzDpVhv32gOhrnwTVvtvdX8Ckg |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwEB7BVrRcECyvQAEjFXEymzix4z2hUroqj66qqki9RY4fEocm230c-PfMZJ1lWxC3KE7s2DOeR-bzDMCBErYupBdciFDzAs03Xvus4IWyeV0rpVVJh5NPp-rkR_H1Ul5G_NMiwip7mdgJatda-kc-QsWNmjfTqRqFCIs4-zz5OLvmVEGKIq2xnMZd2EGtmIoB7Hw6np6db-RyuUYgok2RcjRrRDytl-Z61DaUzTBTHyjj6pZ-ui2lt9TUrbhpp44mD-FBtCPZ4Zrwj-COb4Zwb11Z8tcQ9o76Qm5D2D2N8fPH4FEcEArdO3b185yjludyxkzj2JxSuPa3C214PmMdjJ3qYXm2bBlaimyxmkXgbMPawOiASLvArdJeGUYhAObIonwCF5Pji6MTHgstcIvewpKHYJBeJmgZXJYFPXY-R9dGeWdt5sbO5IWsVXC-yMmdM-TFiNpZl41Lun4Kg6Zt_HNgOmRaGWlK42xRmLGWKfUna-m0CNImcNCvbjVbp9OoujB4riskQkVEqJRO4D2tfEWbbDk31sSzAjgIpauqDinLG7qSUiSwf-NJXFp7s7mnXRU356Iil0rkaPf-u_kPpyXwdtNMHRMerfHtirrIUTSOS5Em8GzNEpv5iDLtvOIE3vU8sjX235N98f-PeAO7yOjV9y_Tby_hPr3TYQnVPgyW85V_hTbRsn4dmf03uM0Gvw |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Increased+miR-155-5p+and+reduced+miR-148a-3p+contribute+to+the+suppression+of+osteosarcoma+cell+death&rft.jtitle=Oncogene&rft.au=Bhattacharya%2C+S&rft.au=Chalk%2C+A+M&rft.au=Ng+A+J+M&rft.au=Martin%2C+T+J&rft.date=2016-10-06&rft.pub=Nature+Publishing+Group&rft.issn=0950-9232&rft.eissn=1476-5594&rft.volume=35&rft.issue=40&rft.spage=5282&rft.epage=5294&rft_id=info:doi/10.1038%2Fonc.2016.68&rft.externalDBID=HAS_PDF_LINK |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0950-9232&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0950-9232&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0950-9232&client=summon |